Lamivudine Maintenance Beyond One Year After Hbeag Seroconversion Is A Major Factor for Sustained Virologic Response in Hbeag-Positive Chronic Hepatitis B
Open Access
- 25 January 2010
- journal article
- viral hepatitis
- Published by Wolters Kluwer Health in Hepatology
- Vol. 51 (2) , 415-421
Abstract
The reported durability of virologic response after successful lamivudine monotherapy is variable, and the question remains as to whether virologic responses can be maintained over an extended follow-up period. The aim of this study was to investigate posttreatment durability, the optimal duration of additional treatment after HBeAg clearance or seroconversion, and determinants for sustained virologic response (SVR) following lamivudine monotherapy in patients with HBeAg-positive chronic hepatitis B (CHB). From January 1999 to August 2004, 178 Korean patients with HBeAg-positive CHB were treated with lamivudine and achieved complete responses, defined as a loss of serum HBeAg and hepatitis B virus DNA, and alanine aminotransferase normalization. The mean duration of lamivudine monotherapy was 26 months (range, 12-77). SVR was maintained in 138 patients (77.5%). Host and viral factors were compared between 138 patients with SVR and 40 patients whose response was not sustained. The cumulative relapse rates increased from 15.9% at 1 year to 30.2% at 5 years, with a mean time to relapse after cessation of lamivudine of 12 months (range, 7-42). Most relapses occurred within 2 years after discontinuation of lamivudine (33/40, 82.5%). On multivariate analysis, age ≤40 years and additional treatment for more than 12 months after HBeAg clearance or seroconversion were independent factors for SVR. Conclusion: The lamivudine-induced virologic response was durable in patients under 40 years old and those receiving lamivudine for more than 12 months after HBeAg clearance or seroconversion. Age and additional treatment were major predictive factors for SVR. (Hepatology 2010.)Keywords
This publication has 26 references indexed in Scilit:
- A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis BNew England Journal of Medicine, 2006
- Virologic response and resistance to adefovir in patients with chronic hepatitis BJournal of Hepatology, 2006
- Four years of lamivudine treatment in Chinese patients with chronic hepatitis BJournal of Gastroenterology and Hepatology, 2004
- Long–Term Follow–Up of Interferon Alfa Treatment in Chinese Patients With Chronic Hepatitis B Infection: the Effect on Hepatitis B E Antigen Seroconversion and the Development of Cirrhosis–Related ComplicationsHepatology, 2001
- Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase regionHepatology, 2001
- Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trialGut, 2000
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- A One-Year Trial of Lamivudine for Chronic Hepatitis BNew England Journal of Medicine, 1998
- Identification and characterization of mutations in hepatitis B virus resistant to lamivudineHepatology, 1998
- Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis BJournal of Medical Virology, 1996